Market Research Logo

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018 provides an overview of Non-Alcoholic Steatohepatitis (NASH) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Non-Alcoholic Steatohepatitis (NASH)
Apr 09, 2018: Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018
Apr 09, 2018: Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)
Apr 05, 2018: Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April
Apr 04, 2018: Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
Apr 04, 2018: Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
Apr 01, 2018: MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis
Mar 28, 2018: GENFIT: Presentations at EASL 2018 Annual Congress Highlight Progress in NASH Diagnostics, Combination Therapies and Deep-learning Applications in Medical Imaging
Mar 28, 2018: Enanta Pharmaceuticals Announces Poster Presentations on EDP-305 at ICL 2018
Mar 28, 2018: Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors
Mar 27, 2018: Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
Mar 23, 2018: Intercept Announces Multiple New Ocaliva (obeticholic acid) Data Presentations at the International Liver Congress 2018
Mar 14, 2018: Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference
Mar 12, 2018: NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018
Mar 12, 2018: Immuron Commences US Non-Deal Institutional Investor Roadshow
Mar 08, 2018: Immuron Reports Positive Results in NASH Clinical Trial
Mar 08, 2018: Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
Mar 08, 2018: Gastrointestinal Hormone Measurably Improved Symptoms of Non-Alcoholic Fatty Liver Disease
Mar 07, 2018: Gencia Will Present Preclinical Results in the DIAMOND Mice Supporting the Therapeutic Potential of Its Lead Mitochondrial Therapeutic, GEN-3026, to Treat NASH at the International Liver Congress
Mar 07, 2018: Cerenis Therapeutics Announces Approval to launch the Phase I Study of repeated and increasing doses to assess CER-209 in NASH/NAFLD
Mar 06, 2018: Can-Fite to Provide Update on Liver Drug Namodenoson at the 30th Annual ROTH Conference
Mar 05, 2018: Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences
Mar 05, 2018: Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer
Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities
Feb 14, 2018: Galmed Announces ARRIVE Study Data
Feb 12, 2018: Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
Feb 12, 2018: Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis
Feb 05, 2018: NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)
Jan 30, 2018: Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress 2018
Jan 28, 2018: MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France
Jan 23, 2018: GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source
List of Tables
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
List of Figures
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
GlobalData Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report